Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.

Publication ,  Journal Article
Mishra, AK; Gupta, A; Dagar, G; Das, D; Chakraborty, A; Haque, S; Prasad, CP; Singh, A; Bhat, AA; Macha, MA; Benali, M; Saini, KS; Previs, RA ...
Published in: Vaccines (Basel)
November 16, 2023

Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have improved the clinical outcomes, the overarching challenge of effecting a comprehensive cure for patients afflicted with relapsed and refractory MM (RRMM) endures. Notably, adoptive cellular therapy, especially chimeric antigen receptor T-cell (CAR-T) therapy, has exhibited efficacy in patients with refractory or resistant B-cell malignancies and is now also being tested in patients with MM. Within this context, the B-cell maturation antigen (BCMA) has emerged as a promising candidate for CAR-T-cell antigen targeting in MM. Alternative targets include SLAMF7, CD38, CD19, the signaling lymphocyte activation molecule CS1, NKG2D, and CD138. Numerous clinical studies have demonstrated the clinical efficacy of these CAR-T-cell therapies, although longitudinal follow-up reveals some degree of antigenic escape. The widespread implementation of CAR-T-cell therapy is encumbered by several barriers, including antigenic evasion, uneven intratumoral infiltration in solid cancers, cytokine release syndrome, neurotoxicity, logistical implementation, and financial burden. This article provides an overview of CAR-T-cell therapy in MM and the utilization of BCMA as the target antigen, as well as an overview of other potential target moieties.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Vaccines (Basel)

DOI

ISSN

2076-393X

Publication Date

November 16, 2023

Volume

11

Issue

11

Location

Switzerland

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mishra, A. K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., … Singh, M. (2023). CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines (Basel), 11(11). https://doi.org/10.3390/vaccines11111721
Mishra, Abhinava K., Ashna Gupta, Gunjan Dagar, Dayasagar Das, Abhijit Chakraborty, Shabirul Haque, Chandra Prakash Prasad, et al. “CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.Vaccines (Basel) 11, no. 11 (November 16, 2023). https://doi.org/10.3390/vaccines11111721.
Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, et al. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines (Basel). 2023 Nov 16;11(11).
Mishra, Abhinava K., et al. “CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.Vaccines (Basel), vol. 11, no. 11, Nov. 2023. Pubmed, doi:10.3390/vaccines11111721.
Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, Prasad CP, Singh A, Bhat AA, Macha MA, Benali M, Saini KS, Previs RA, Saini D, Saha D, Dutta P, Bhatnagar AR, Darswal M, Shankar A, Singh M. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines (Basel). 2023 Nov 16;11(11).

Published In

Vaccines (Basel)

DOI

ISSN

2076-393X

Publication Date

November 16, 2023

Volume

11

Issue

11

Location

Switzerland

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences